Related Experiment Video
Updated: Jul 1, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders
David T Liebers1,2, Tianshe He1,3, Rebecca A Betensky4
1Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York.
JAMA Network Open
|June 30, 2026
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce dementia risk in individuals with psychiatric disorders. This study found SGLT2 inhibitor use was linked to lower dementia and psychiatric emergency department visit rates.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Individuals with mood and psychotic disorders face elevated dementia risk.
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors possess mitochondrial and metabolic properties suggesting potential neuroprotection.
Purpose of the Study:
- To investigate the association between SGLT2 inhibitor treatment and the risk of incident dementia in patients with psychiatric disorders.
- To evaluate the impact of SGLT2 inhibitors on other neuropsychiatric outcomes, including psychiatric emergency department visits and hospitalizations.
Main Methods:
- A cohort study emulating a target trial using US Department of Veterans Affairs data (2016-2024).
- Inclusion criteria: patients aged 65+ with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder, without prior dementia or SGLT2 inhibitor use.
- Marginal structural models with inverse probability of treatment and censoring weighting were employed.
Main Results:
- SGLT2 inhibitor use was associated with reduced odds of all-cause dementia (OR, 0.61; 95% CI, 0.52-0.73) in intention-to-treat analysis.
- Sustained SGLT2 inhibitor use (per-protocol analysis) also showed lower odds of dementia (OR, 0.54; 95% CI, 0.40-0.73) and psychiatric hospitalizations (OR, 0.56; 95% CI, 0.31-1.00).
- A significant reduction in psychiatric emergency department visits was observed (OR, 0.80; 95% CI, 0.66-0.97).
Conclusions:
- SGLT2 inhibitor use is associated with a lower risk of dementia in older adults with mood and psychotic disorders.
- Findings suggest a potential neuroprotective role for SGLT2 inhibitors in this high-risk psychiatric population.
- Further research is warranted to confirm these neuroprotective effects.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:55Secondary Active Transport
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...